Vascular Biogenics Ltd Virtual R&D Day & Corporate Update Transcript
Good day, everyone, and welcome to the VBL Therapeutics 2021 Virtual R&D Day. With us today are Professor Dror Harats, Chief Executive Officer; Dr. Bradley Monk, Chair of the OVAL Steering Committee; and Dr. Tami Rachmilewitz, Vice President of Clinical Development. As a reminder, following the conclusion of today's event, we'll have an archived webcast available under the Events and Presentations section of the VBL IR website.
With that said, it's now my pleasure to turn the call over to Professor Harats for opening remarks. Dror?
Thank you, Lee. And good morning, everybody, and welcome for our VBL's R&D Day. In this short session of about 2 hours, I will give a company overview, and then Dr. Tami Rachmilewitz, our VP, Clinical Development, will talk about VB-111 in ovarian cancer. And then, of course, our distinguished guest, Professor Bradley Monk, the Chair of our OVAL Steering Committee, is going to actually talk about how VB-111 fits into the ovarian cancer landscape, and then
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |